Galapagos gets another Milestone Payment from Gilead

09/12/2016 - 2 minutes

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors?

Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news from its collaboration with Gilead: filgotinib has started a Phase IIb/III trial in ulcerative colitis. With this successful step in clinical development, Galapagos will receive a €9.4M milestone payment.

Filgotinib is already in Phase III for rheumatoid arthritis and Crohn’s disease. Although rheumatoid arthritis is a big market expected to hit an overwhelming €76B ($80.7B) by 2020, it is already crowded with big players. Humira (adalimumab), the top-selling drug developed by AbbVie, generated €13B ($14B) last year, and will soon be replaced by biosimilars in the pipelines of Boehringer Ingelheim, MSD, Amgen, Pfizer and Novartis’

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member